Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.34 |
| ▸ | FEN1 | P39748 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12223936 | 0.96 | FPR2 (0.34) | FPR2ALOX5APFEN1PTGS1PTGS2 | |
| SCHEMBL10303398 | 0.95 | TP53 (0.34) | FPR2ALOX5APFEN1ACACBTP53 | |
| SCHEMBL12223403 | 0.95 | TP53 (0.34) | FPR2ALOX5APFEN1ACACBTP53 | |
| SCHEMBL12223974 | 0.94 | FPR2 (0.33) | FPR2ALOX5APFEN1PTGS1PTGS2 | |
| SCHEMBL11939324 | 0.93 | CNR2 (0.37) | ALOX5APFEN1 | |
| SCHEMBL11939352 | 0.93 | CNR2 (0.37) | ALOX5APFEN1 | |
| SCHEMBL11939195 | 0.90 | ACACB (0.34) | FPR2ALOX5APFEN1ACACB | |
| SCHEMBL12224609 | 0.90 | GPR119 (0.37) | ALOX5APFEN1ACACB | |
| SCHEMBL11939000 | 0.90 | KDM1A (0.37) | FPR2PTGS1PTGS2TP53 | |
| SCHEMBL12223926 | 0.90 | GPR119 (0.37) | ALOX5APFEN1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033937-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FPR2 804/4885ALOX5AP 903/4885FEN1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.